Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Abdulla A. Damluji, MD, PhD Profile picture
@DrDamluji
Nov 5, 2021 • 26 tweets • 17 min read • Read on X
Scrolly
SURTAVI

No differences in death ,stroke, MI, or HF between TAVR and Surgery during longer follow-up

#TCT2021
Hemodynamics

Total AR and PVL

KCCQ no difference after 1 year

NYHA class at one year 1
Summary for SURTAVI

Self expanding valve

#TCT2021
Excellent!
5 year data for 4,000 patients is now out (intermediate risk).

@djc795
Economic outcomes of PARTNER #3

@djc795

Cost effectiveness study along side of PARTNER 3 trial

funded by Edwards
Costing: definitions

US population only

Medicare data link
Results Baseline

TAVR vs SAVR PARTNER 3 Economic Study
Index Hospital Costs

Follow-up Cost
Overall no cost difference

QALY difference (borderline?!)

#TCT2021
All costs and effects discounting

TAVR is cost effective
Subgroups (pre-specified)

Sensitivity analyses

#TCT2021
Sensitivity Analyses
Summary!

84% CI that we will improve outcomes and at the same time achieve cost effectiveness.

10 year outcomes will affect cost effectiveness - to come...

Outstanding presentation @djc795 @DrMauricioCohen

#TCT2021
"When mortality rate is the same between SAVR and TAVR: patient preference is what matter next."

"No one wants a sternotomy."

@djc795

#TCT2021
CHOICE CLOSURE

Vascular Closure for TAVR but this also applies to shock space also (Safety Bundle)

#TCT2021

@Radial_ICG @behnam_tehrani @agtruesdell @ShashankSinhaMD @JACCJournals
Available Evidence

Aim Choice Closure

Randomization: pure plug based vs primary suture based

#TCT2021
Inclusion and Exclusion

Primary Endpoint
Secondary Endpoints

Study Methods

Angioseal was used...

3 Locations in Germany

#TCT2021
Study Flow

258 MANTA vs 258 ProGlide

#TCT2021
Baseline Results

Vessel Characteristics

Procedural Details

Low ultrasound use?! @Radial_ICG

#TCT2021
Manta had higher complications!!

Important data!

#TCT2021
Subgroup analysis

Hospital Outcomes

30-Day Outcomes

#TCT2021
Limitation
Conclusion

Excellent trial @Mo_A_W

Applies to shock too

***Editorializing: Losing the wire access with MANTA is a big problem.

#SafetyBundle

#TCT2021
Comparison of a Pure Plug-Based versus a Primary Suture-Based Vascular Closure Device Strategy for Transfemoral Transcatheter Aortic Valve Replacement: The CHOICE-CLOSURE Randomized Clinical Trial

@CircAHA

ahajournals.org/doi/abs/10.116…

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Abdulla A. Damluji, MD, PhD

Abdulla A. Damluji, MD, PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DrDamluji

Abdulla A. Damluji, MD, PhD Profile picture
Dec 18
Lipid-Lowering Therapies and Cognition in Older Adults: A Narrative Review and Clinical Considerations: @Sciencedirect

🥸 This is a new manuscript from our team ~ led by @MichaelGNanna on ALL lipid lowering therapy and cognitive function.

😱 Very nicely done by @heartwiselab team.

🥸Here is a summary

👇👇👇Image
🥸1️⃣ Lipid-lowering therapy is a cornerstone of cardiovascular risk reduction in older adults. However, concerns about possible cognitive side effects, especially in the setting of aggressive low-density lipoprotein cholesterol reduction, persist among patients and clinicians.
🥸2️⃣ Statins have been the primary focus of this concern. While early case reports described memory loss and attention deficits, subsequent systematic evaluations have found no consistent evidence that statins impair cognition in older adults.
Read 22 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Nov 21
Social Determinants of Cardiovascular Aging: @JACCJournals

🥸 Great work led by Aaron Troy on social determinants of an aging population.

😱 Summary below

👇👇👇👇 Image
🥸1️⃣Social and economic conditions shape cardiovascular aging as strongly as traditional risk factors. These exposures begin early, accumulate over decades, and alter vascular, myocardial, valvular, and electrophysiologic aging trajectories.
🥸2️⃣Cardiovascular aging follows distinct paths depending on structural determinants such as race, gender, education, and geography. These determinants influence baseline risk, access to care, biologic stress, and clinical expression of disease.
Read 21 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Oct 1
Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology: @JACCJournals and @ACCinTouch

🥸 Inflammation and aging are interlinked: #inflammaging

😱 Great science statement here

👇👇👇 Image
🥸 1️⃣ Inflammation and cardiovascular disease frames risk beyond cholesterol; residual inflammatory risk by hsCRP often persists despite statins, so a patient with LDL at goal but hsCRP 3–5 mg/L still faces higher event rates and needs a plan that targets inflammation directly.
🥸 2️⃣ hsCRP behaves like blood pressure or LDL in risk tools; use <1, 1–3, >3 mg/L as low, intermediate, high relative risk, and repeat any value >10 mg/L after infections settle so you act on a stable baseline rather than a transient spike.
Read 21 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Sep 7
Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis: @TheLancet

🥸Plavix for secondary prevention may be superior to aspirin

😱 Summary

👇👇👇 Image
🥸1️⃣ For decades, aspirin has been the default long-term therapy for preventing recurrent cardiovascular events in patients with established coronary artery disease. It has been embedded in clinical guidelines based largely on historical data.
🥸2️⃣ However, multiple randomized trials have recently compared clopidogrel directly with aspirin as a single-agent strategy. This 2025 meta-analysis provides the most comprehensive assessment to date by combining patient-level data.
Read 21 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Sep 3
Global Uptake of GLP-1 Receptor Agonists in Obese, Non-Diabetic Patients with Cardiovascular Disease: @ESC_Journals

🥸New publication from our @heartwiselab research group: @MichaelGNanna

😱Older adults use: 1.9% of semaglutide and 1.3% of tirzepatide - summary

👇👇👇 Image
🥸1️⃣ GLP-1 receptor agonists (GLP-1RAs) were originally developed for diabetes and weight loss. SELECT expanded their role, showing semaglutide reduces cardiovascular events in non-diabetic patients with obesity and established cardiovascular disease.
🥸2️⃣ SELECT enrolled 17,604 adults ≥45 years with overweight or obesity (BMI ≥27) and prior MI, stroke, or PAD, but no diabetes. Semaglutide led to a 20% relative risk reduction in major adverse cardiovascular events.
Read 21 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Aug 30
Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias: @NEJM

🥸 The statement: "Keep K above 4 and Mg above 2" still holds: #ESCCongress2025

😱 Summary

👇👇👇 Image
🥸1️⃣ The POTCAST trial tested if raising potassium to the high-normal range (4.5–5.0 mmol/L) reduces malignant arrhythmias, hospitalizations, or death in patients with cardiovascular disease and an implanted defibrillator.
🥸2️⃣ It was a randomized, multicenter trial in Denmark enrolling 1,200 patients with potassium ≤4.3 mmol/L and an implantable cardioverter-defibrillator for primary or secondary prevention.
Read 21 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

Send Email!

:(